Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today reported financial and operational results for the third quarter ended September 30, 2019. Q3 2019 Revenues of $1.87 million saw a 13% sequential increase over Q2 2019, and a 0.6% decrease compared to Q3 2018.
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it plans to release its third quarter 2019 financial results after market close on Tuesday, November 12, 2019.
Chronic care management company Livongo has inked a deal with the U.S. government, giving federal employees insured by the government with Type 1 or Type 2 diabetes access to the digital program. The Livongo for Diabetes tool will be open to those insured under the Blue Cross and Blue Shield Federal Employee program, which covers roughly 5.3 million people.
#insurance
#dtx
#coaching
Digital chronic disease management company Omada Health has added onto June’s $73 million funding round with a new strategic investment from Intermountain Ventures. The terms of the deal were not disclosed.
Digital chronic disease management company Livongo Health announced a partnership today with VSP Vision Care that will blend each service for the companies’ mutual clients. More specifically, Livongo members with diabetes who are also under “most” VSP plans will be offered retinal screenings from VSP network doctors, and receive messages through the digital program prompting them to seek eye care through a VSP tool. Additionally, Livongo will be providing its programs for diabetes, hypertension and behavioral to VSP employees and their dependents.
#product & service
#dtx
#virtual care
Abbott and Omada Health announced they are partnering to integrate Abbott’s revolutionary FreeStyle Libre system, a CGM technology, with Omada Health’s pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes. Omada Health will offer the integrated solution to employers and health plans. People diagnosed with Type 2 diabetes who are eligible will be guided through a tailored experience that includes an online physician consultation, obtaining a prescription of Freestyle Libre and delivery of a welcome kit that includes the CGM system and a wireless scale.
#connected device
#coaching
#cgm
Chronic care management company Livongo is now looking to integrate virtual care into its platform, announcing a new deal with telemedicine giants MDLive and Doctor on Demand.
#product & service
#coaching
#telehealth
Life insurer John Hancock has unveiled a new wearable program dubbed Aspire aimed at helping its members with diabetes manage the condition. The program was born out of a partnership with Verily and digital diabetes care platform Onduo. Users of the new platform can access diabetes coaching via Onduo’s virtual clinic. The program also has fiscal rewards. According to the company, members using the service can save up to 25% on their annual insurance premiums through healthier behaviors and life styles. Participants in the program will get rewards for maintaining a healthy A1c level or by making progress toward their target A1c level.
#insurance
#coaching
#telehealth
LifeScan today announced a new engagement with Willis Towers Watson to expand the adoption of OneTouch Reveal Plus, the digital diabetes therapeutic powered by Welldoc’s award-winning BlueStar platform. Through this collaboration, the companies will seek to support self-insured employers help their employees and dependents manage their diabetes in an effort to improve outcomes and reduce treatment costs. This partnership will also include a new subscription test strip bundle option for patients. Currently, OneTouch Reveal® Plus is indicated for use with adult patients with type 2 diabetes. LifeScan and Welldoc are working to expand the app’s digital capabilities and connectivity with the goal of pursuing FDA clearance to include type 1 diabetes and, potentially, other conditions.
#product & service
#mobile app
#coaching
Nemaura Medical, Inc., a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona.
#cgm